Seattle Genetics has developed an industry leading antibody-drug conjugate technology that is designed to enhance the ability of monoclonal antibodies to target cancer cells to deliver cell-killing agents. The technology has been praised as it reduces the toxic effects of traditional chemotherapy approaches due to its ability to avoid killing non-targeted cells.
The ADC technology is also very popular amongst the pharmaceutical industry, in 2011 Pfizer signed a collaboration with Seattle Genetics to license the technology and in 2013 a second major agreement was put together with Bayer for it to exclusively license its auristatin based ADC technology with antibodies to several targets. Bayer paid an upfront fee of $20million, whilst Seattle stand to receive up to $500million in milestone payments and royalties on the net sales of any resulting products globally. Licensing partnerships for the technology have also been signed with Abbvie, Celldex, Daiichi-Sankyo, Millenium,GSK, Genentech and Progenics.
As well as its collaborations, Seattle does develop its own antibody based products but it could just as easily sit back and take in the profits from product royalties that have been developed by companies using its technology. The company currently has 15 deals in place and its licensing agreements have made more than $250million.
Seattle’s main product is Adcetris® an antibody that is commercially available to treat both relapsed Hodgkin’s lymphoma and relapsed system anaplastic large cell lymphoma. The product has been a huge success and is available in more than 40 countries including USA, Canada and Japan.
6 other clinical candidates are in development in the company’s pipeline to treat breast and bladder cancer amongst other things.
Although Seattle licenses its technology out to many companies it also works with some companies to co-develop new candidates, it is jointly discovering novel ADC’s for cancer with Oxford Biotherapeutics and has in opt-in rights for ADC product candidates developed within its collaborations with Agensys and Genmab.
Naturally there are many collaboration opportunities available for companies to work with Seattle Genetics and it is also looking to in-license some further oncology candidates.
Seattle Genetics is often present at a large number of partnering events throughout the year.
Partnering events are a great place to meet lots of potential partners face to face in a short space of time.
Events with Seattle Genetics presence include but are not limited to:
- BIO International Convention and Business Forum
- BioEurope / BioEurope Spring
For a full list of forthcoming partnering events where you could meet with Seattle Genetics in person visit Current Partnering’s Event calendar.
Contacting Seattle Genetics for partnering
Seattle Genetics can be contacted in relation to partnering through a number of channels. Here is a list of the most common channels:
Partnering events: face to face contact is generally considered the most effective form of contact. Partnering events not only allow face to face contact but also contact with multiple companies for the price of one flight and hotel reservation. This benefit makes partnering events the most cost effective method of making personal introductions as a start point for partnering discussions.
See Current Partnering’s event calendar for details of forthcoming events.
Direct contact: there are several sources of direct contact with Seattle Genetics’s business development team
- Phone: Picking up the phone and speaking with an individual is the best form of non-face to face contact as it allows your name and voice to be remembered and associated with an opportunity.
- Email: Sending an email is another good way of making contact. Ideally, research the individual responsible for the therapy/technology area being targeted and get in touch. Email contact to a named individual view the list of contacts at Seattle Genetics’ website for details.
- LinkedIn: Business to business contact is increasingly taking place via LinkedIn, the global online networking channel.
Many of Seattle Genetics’s business development executives have LinkedIn profiles and can be found by viewing the company’s profile. Visit Seattle Genetics LinkedIn page here.
Opportunity submission form: the least favourable channel but worth using if you do not have access to the other channels mentioned above. This is the form available on the Seattle Genetics website for potential partnering opportunities.
Seattle Genetics partnering at Current Agreements
Full details on each deal can be found at Current Agreements (subscription required)
No M&A activity for Seattle Genetics
Available reports from Current Partnering
Report: Partnering Deals and Alliances with Seattle Genetics
Report: Partnering Deals and Alliances with Big Biotech
Available resources for deal coverage for Seattle Genetics
Read: more on Seattle Genetics company profile, recent partnering, M&A and financing news and articles
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk